Tim Walbert, Horizon CEO (via YouTube)
August 3, 2022 03:02 PM EDTUpdated 03:38 PM
R&D
Pharma

Hori­zon low­ers ex­pec­ta­tions for Te­pez­za and ad­justs its strat­e­gy for the year ahead

Tyler Patchen

News Reporter

One of Hori­zon Ther­a­peu­tics’ top sell­ers isn’t per­form­ing as well as ex­pect­ed, CEO Tim Wal­bert re­vealed on Wednes­day’s Q2 call, lead­ing the phar­ma com­pa­ny to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times